Post-marketing surveillance has included reports of: Irritability Mood changes Emotional flattening Anxiety However: These reports are uncommon They do not prove causation They often involve other contributing factors After reviewing these reports, both the FDA and European Medicines Agency concluded there is no clear causal linkbetween GLP-1 medications and serious mood or behavioral disorders, but they recommend clinical monitoring, especially in patients with a psychiatric history
Key Takeaways Ozempic and Wegovy can cause eye-related side effects such as blurred vision, dry eyes, and changes in vision
The 0.5% discontinuation rate suggests most users will complete their treatment course without significant tolerability issues
American Enterprise Institute
Studies published in journals accessible suggest GLP-1 agonists can reduce markers of systemic inflammation
Semaglutide (Wegovy): Designed for weight loss, clinical trials show an average reduction of 1520% of body weight over 612 months with proper diet and exercise